Raymond James Financial’s Cognition Therapeutics CGTX Stock Holding History

Raymond James Financial’s Portfolio CGTX Stock Details CGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$36.1K	Sell	47,500 -1,000	-2%	-$1.16K	﹤0.01%	5153
2025 Q4	$65.5K	Buy	48,500 +18,859	+64%	+$30.6K	﹤0.01%	4984
2025 Q3	$40K	Buy	29,641 +7,641	+35%	+$10.4K	﹤0.01%	4845
2025 Q2	$6.82K	Buy	22,000 +1,000	+5%	+$338	﹤0.01%	6069
2025 Q1	$8.84K	Buy	21,000 +3,500	+20%	+$2.06K	﹤0.01%	4784
2024 Q4	$12.3K	Buy	+17,500	New	+$8.65K	﹤0.01%	4763

Other funds holding CGTX

BCM

BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HCM

Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

DIG

Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Raymond James Financial's CGTX Position: Q1 2026 in Review

Raymond James Financial reduced its Cognition Therapeutics (CGTX) stake by 2.1% in Q1 2026, selling an estimated $1.16K and leaving 47,500 shares worth $36.1K. The position accounts for ﹤0.01% of the portfolio, ranked #5153.

Raymond James Financial first reported a position in CGTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $65.5K in Q4 2025. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

Raymond James Financial held 47,500 shares of Cognition Therapeutics worth $36.1K as of Q1 2026.
Raymond James Financial sold 1,000 Cognition Therapeutics shares in Q1 2026, an estimated $1.16K.
Cognition Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #5153 holding.
Raymond James Financial first reported a position in Cognition Therapeutics in Q4 2024 and has held it in 6 quarters since.
Raymond James Financial's Cognition Therapeutics position peaked at $65.5K in Q4 2025.
75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.